receptor antagonist (IC50
values are 19, 21, and 80 nM respectively). Also inhibits p38 MAPK (IC50
= 187 - 400 nM) and phosphodiesterase type 4D (IC50
= 22 nM). Displays potent anti-inflammatory effects in vitro
and in vivo
. Potentially useful for asthma and chronic obstructive pulmonary disease (COPD) research.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.
Trifilieff et al.